Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Gomard

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Virology|April 29, 1998
Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patientsD Durali, J Morvan, F Letourneur, et al.
Vaccine|April 1, 1996
Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTLB Deprez, J P Sauzet, C Boutillon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1992
Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoproteinF Martinon, H Gras-Masse, C Boutillon, et al.
AIDS Research and Human Retroviruses|July 22, 1998
Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivoJ P Sauzet, C Moog, A Krivine, et al.
Human Immunology|March 1, 1986
Despite lack of monospecific anti-DRw13 sera, a corresponding class II determinant can be defined by a DRw13 restricted anti-influenza virus T cell cloneJ Michon, G Sterkers, A Haziot, et al.
The Journal of Infectious Diseases|July 4, 1998
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapyM Dalod, M Harzic, I Pellegrin, et al.
AIDS (London, England)|November 1, 1992
Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteinsS Lamhamedi-Cherradi, B Culmann-Penciolelli, B Guy, et al.
Lancet (London, England)|June 17, 1999
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study groupY Levy, C Capitant, S Houhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1997
Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigensH de la Salle, E Houssaint, M A Peyrat, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Virology|April 29, 1998
Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patientsD Durali, J Morvan, F Letourneur, et al.
Vaccine|April 1, 1996
Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTLB Deprez, J P Sauzet, C Boutillon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1992
Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant. Immune response of BALB/c mice to human immunodeficiency virus envelope glycoproteinF Martinon, H Gras-Masse, C Boutillon, et al.
AIDS Research and Human Retroviruses|July 22, 1998
Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivoJ P Sauzet, C Moog, A Krivine, et al.
Human Immunology|March 1, 1986
Despite lack of monospecific anti-DRw13 sera, a corresponding class II determinant can be defined by a DRw13 restricted anti-influenza virus T cell cloneJ Michon, G Sterkers, A Haziot, et al.
The Journal of Infectious Diseases|July 4, 1998
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapyM Dalod, M Harzic, I Pellegrin, et al.
AIDS (London, England)|November 1, 1992
Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteinsS Lamhamedi-Cherradi, B Culmann-Penciolelli, B Guy, et al.
Lancet (London, England)|June 17, 1999
Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study groupY Levy, C Capitant, S Houhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1997
Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigensH de la Salle, E Houssaint, M A Peyrat, et al.
Pageof 6